Higher NfL levels, reliable biomarkers of axonal damage across a variety of neurological disorders, reflect a more disease burden and neuronal pool impairment [24] and could be a potential biomarker for patients’ stratification in MSA drug trials [13]. Here, NEFL is linked to multiple system atrophy.